ArticleCureus2025
Acute Generalized Exanthematous Pustulosis With Negative Patch Test and Drug-Induced Lymphocyte Stimulation Test (DLST) Results: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute generalized exanthematous pustulosis (AGEP) is a rapid-onset skin disorder characterized by edematous erythema, mainly affecting intertriginous areas and the face, along with sterile, non-follicular pustules. It is most often drug-induced, commonly triggered by antibiotics, anticancer agents, or hydroxychloroquine. Symptoms typically appear within a few days of drug exposure. Histologically, AGEP features spongiform pustules in or beneath the stratum corneum, papillary dermal edema, and perivascular neutrophilic infiltration. Patch testing and drug-induced lymphocyte stimulation test (DLST) are used to identify the causative agent, although both may yield false-negative results. We report a case of AGEP occurring two days after administration of paclitaxel, oral iron, and vonoprazan. All three drugs were discontinued, and the patient responded well to topical corticosteroids and oral prednisolone. Patch tests for all agents were negative. However, based on previous reports of severe vonoprazan-induced drug eruptions and the lack of evidence linking paclitaxel or oral iron to AGEP, vonoprazan was considered the most likely culprit. Since the patient wished to continue cancer treatment, paclitaxel and oral iron were cautiously reintroduced with informed consent and close monitoring. No recurrence occurred, further supporting vonoprazan as the causative agent. This case highlights the limitations of patch testing and DLST in AGEP diagnosis and emphasizes the importance of clinical context and therapeutic priorities in evaluating drug causality. Further studies are needed to standardize AGEP testing protocols and improve diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.